Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors
Carmine Fedele(American Institutes for Research), Claudia De Lorenzo(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Carmela Coppola, Carlo G. Tocchetti(Federico II University Hospital), Antônio Barbieri, Gennaro Riccio(Sapienza University of Rome), Nicola Maurea(Cancer Institute (WIA)), Claudio Arra(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), M. Monti(Federico II University Hospital), Giuseppe D’Alessio(Federico II University Hospital)
Cited by 52
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Fish Waste: From Problem to Valuable Resource
|Marine Drugs|2021|568